Home Parenteral Nutrition in Cancer Patients
This study is being done to examine the effect of Parenteral (intravenous) nutrition support in the home setting on quality of life in cancer patients. In addition, this study is being done to examine the effect of home parenteral nutrition on the use of pain and anti-nausea medication.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||An Evaluation of Quality of Life Outcomes in Cancer Patients Receiving Home Parenteral|
- Quality of Life [ Time Frame: Monthly for a minimum of 3 months to a maximum of 12 months ] [ Designated as safety issue: No ]To examine the effect of parenteral nutrition support in the home care setting on quality of life as measured by the EORTC QLQ-C30
- Pain and nausea medication usage [ Time Frame: Monthly for a minumum of 3 months to a maximum of 12 months ] [ Designated as safety issue: No ]To examine the effect of home parenteral nutrition on the use of pain medication and anti-emetic therapy administered intravenously, subcutaneously, or orally.
|Study Start Date:||May 2010|
|Study Completion Date:||June 2013|
|Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Home Parenteral Nutrition
Patients receiving home parenteral nutrition
Dietary Supplement: Home Parenteral Nutrition
Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
Other Name: Intravenous nutrition
This is a prospective descriptive non-randomized clinical study to examine quality of life outcomes and use of pain and anti-emetic therapy for patients receiving HPN support. The EORTC QLQ-C30 will be used to evaluate quality of life. All subjects will be monitored monthly throughout the course of treatment for a minimum of 3 months and a maximum of 1 year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01152879
|United States, Oklahoma|
|Cancer Treatment Centers of America at Southwestern Regional Medical Center|
|Tulsa, Oklahoma, United States, 74133|
|Principal Investigator:||Ross Taylor, MD||Cancer Treatment Centers of America at Southwestern Regional Medical Center|